Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma

• DOI: 10.1038/srep41624
• Publication Date: 2017-02-03T12:50:58Z
• Authors: Lei Jianyong; Zhong Jinjing; Yan Lunan; Zhu Jingqiang; Wang Wentao; Zeng Yong; Li Bo; Wen Tianfu; Yang Jiaying
• Keywords: Adult; Male; Carcinoma, Hepatocellular; Kaplan-Meier Estimate; Article; 03 medical and health sciences; 0302 clinical medicine; Meta-Analysis as Topic; Recurrence; Cause of Death; Preoperative Care; Humans; Chemoembolization, Therapeutic; Aged; Neoplasm Staging; Liver Neoplasms; Middle Aged; Combined Modality Therapy; Survival Analysis; Liver Transplantation; 3. Good health; Catheter Ablation; Female; Follow-Up Studies

Combinations of transarterial chemoembolization (TACE) and radical therapies (pretransplantation, resection radiofrequency ablation) for hepatocellular carcinoma (HCC) have been reported as controversial issues in recent years. A consecutive sample 1560 patients with Barcelona Clinic Liver Cancer (BCLC) stage A/B HCC who underwent solitary Radiofrequency ablation (RFA), or liver transplantation (LT) adjuvant pre-operative TACE were included. The 1-, 3- 5-year overall survival rates tumor-free comparable between the therapy group combined whole each subgroups (RFA, LT) (P > 0.05). In subgroup analysis, according to BCLC B, advantages also not observed Neutrophil-lymphocyte ratio (NLR) more than 4, multiple tumor targets, poor histological grade significant contributors rates. conclusions, our results indicated that preoperative did prolong long-term survival, but LT should nevertheless be considered first choice B patients. Radical performed very carefully